Valenta Antiviral Medicine Led the Segment by Retail Sales in the First Four Months of 2016

Valenta Antiviral Medicine Led the Segment by Retail Sales in the First Four Months of 2016

06.06.2016

According to the audit made by DSM Group analytical agency, Valenta’s Ingavirin® took the first position among antiviral medicines for flu in value terms of sales at the pharmaceutical outlets of Russia in January-April 2016. Sales of Ingavirin® grew 37% in comparison with the same period of 2015. In April, the medicine also took the leading positions in value terms of sales.

Besides, in January-April 2016, growth of retail sales in number of sold packages of Ingavirin® was registered. This parameter increased more than 1.4 times.